← All trials
NCT07286266
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 3, 2026
- Primary completion
- Jan 16, 2030
- Completion date
- Jan 16, 2030
- First posted
- Dec 16, 2025
- Last posted
- Dec 16, 2025
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
- European Network for Gynaecological Oncological TrialCollaborator
- GOG Foundation, Inc.Collaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.